Search results
Investing in Immutep (ASX:IMM) three years ago would have delivered you a 47% gain
Simply Wall St. via Yahoo Finance· 2 years agoBy buying an index fund, you can roughly match the market return with ease. But if you choose...
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
Simply Wall St. via Yahoo Finance· 6 months agoFor many, the main point of investing is to generate higher returns than the overall market. But...
Here's Why Immutep Limited's (ASX:IMM) CEO Compensation Is The Least Of Shareholders' Concerns
Simply Wall St. via Yahoo Finance· 2 years agoCEO Marc Voigt has done a decent job of delivering relatively good performance at Immutep Limited...
With 49% stake, Immutep Limited (ASX:IMM) seems to have captured institutional investors' interest
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Significantly high institutional ownership implies Immutep's stock price is sensitive...
Immutep Limited (ASX:IMM): Is Breakeven Near?
Simply Wall St. via Yahoo Finance· 8 months agoImmutep Limited (ASX:IMM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Immutep...
The past year for Immutep (ASX:IMM) investors has not been profitable
Simply Wall St. via Yahoo Finance· 1 year agoImmutep Limited (ASX:IMM) shareholders should be happy to see the share price up 12% in the last...
The 12% return this week takes Immutep's (ASX:IMM) shareholders three-year gains to 96%
Simply Wall St. via Yahoo Finance· 12 months agoBy buying an index fund, you can roughly match the market return with ease. But if you buy good...
Immutep First Half 2023 Earnings: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)
Simply Wall St. via Yahoo Finance· 1 year agoImmutep (ASX:IMM) First Half 2023 Results Key Financial Results Net loss: AU$20.6m (loss widened by...
Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants
Benzinga via Yahoo Finance· 2 years agoImmunome Inc (NASDAQ: IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against...
Why This Small-Cap Stock Is Gaining More Than 10% Today?
Benzinga via Yahoo Finance· 2 years agoChardan has initiated coverage of Immuneering Corp (NASDAQ: IMRX) with a Buy rating and a price...
